Kornimate/medical-research-clean huggingface dataset:
flualert: influenza vaccine alerts for providers in the electronic health record

Conditions: Influenza

Summary: childhood influenza coverage rates are far below rates for the other childhood vaccinations. increasing influenza vaccine coverage rates is important not only for the health of the child, but for that of the child's household and community. yet,influenza vaccine delivery rates at pediatric clinics are low, even when the vaccine is available. the proposed project will take advantage of existing health information technology to tailor, implement and evaluate influenza vaccine alerts in the electronic health record (ehr) for pediatric providers to help improve health care decision making.


Eligibility criteria:
inclusion criteria: * medical (medical doctor/nurse practitioner (md/np)) or nursing providers (registered nurse, licensed practical nurse (rn/lpn)) at participating practices * parents of a child 6 months - 18 years who is a patient at one of the participating acn practice * parents fluent in english or spanish * children 6 months- 18 years with visit to participating practice during influenza season

Keywords: influenza, vaccine, clinical decision support
a post-market study for long-term effectiveness and safety of the ntx100 for rls

Conditions: Restless Legs Syndrome

Summary: multi-center post-market, observational study to assess the long-term effectiveness and safety of the ntx100 tomac system for patients with restless legs syndrome.

this study will assess the ntx100 tomac system's long-term effectiveness and safety in real-world settings. using a prospective, observational approach, we'll monitor individuals receiving the system as part of standard care through five study visits, collecting data on clinical outcomes, device performance, and adverse events.

Eligibility criteria:
inclusion criteria: 1. the subject possesses the necessary equipment, internet/phone accessibility, and communication ability to complete electronic questionnaires and respond to electronic communications and phone calls from the research staff throughout the in-home portion of the study. 2. the subject has signed a valid, irb-approved informed consent form, can understand the requirements of the study and instructions for device usage, and can converse in english. 3. diagnosis of restless legs syndrome. exclusion criteria: 1. the subject is unable or unwilling to comply with study requirements.

Keywords: rls
skin stretch sensory stimuli and tens in diabetic neuropathy

Conditions: Diabetic Neuropathy

Summary: the aim of the research was to find and compare the effects of skin stretch sensory stimuli and transcutaneous electrical nerve stimulation (tens) on balance in diabetic neuropathy. randomized controlled trial done at district headquarter hospital okara. the sample size was 46. the subjects were divided into 3 groups, 15 subjects in skin stretch sensory stimuli group, 15 subjects in tens group and 16 subjects in control group. study duration was of 6 month. sampling technique applied was convenient non-probability sampling. patients aged range from 45 to 80 years, having moderate peripheral neuropathy, and decrease sensations were included. tools used in this study were berg balance scale and toronto clinical neuropathy score system. data was being analyzed through spss 21.

literature shows that various studies was done on diabetic patients for pain reduction, increase proprioception, improve muscle function and muscle recruitment by using kinesio tape and transcutaneous electrical nerve stimulation. there is particularly limited literature available on the effects of skin stretch sensory stimuli on balance in dn patients. therefore, based on the literature study, there is crucial need for studying the effects of skin stretch sensory stimuli and tens as a treatment approach. thus, the current study will be an attempt to know the results of skin stretch sensory stimuli and tens in dn patients.

Eligibility criteria:
inclusion criteria: * participants age ranged from 45 to 80 years' old * both genders. * patients with moderate peripheral neuropathy 9-11 on toronto clinical neuropathy scoring system * hba1c levels * peripheral neuropathic pain of \>6 months' duration involving the lower extremities * history of diabetes treated with diet, oral hypoglycemic or insulin therapy * lower extremity symptoms such as muscle pain, decrease in sensations, achilles tendon reflex, joint position sense of thumb * sensory polyneuropathy because of type 2 diabetic diseases * ability to walk household distance without assistance or with the use of assistive device such as cane. exclusion criteria: * considerable musculoskeletal deformity such as fracture, amputation, abnormality of rom. * previous history of knee or back surgery * lower extremity arthritis that prevents standing * history of cardiovascular problems such as angina, mi * symptomatic postural hypotension * foot ulceration. * skin problems such as rashes etc.

Keywords: diabetic neuropathy tens kinesiotape balance
dronabinol versus placebo in treatment and prevention of highly active anti-retroviral therapy (haart)-related nausea and vomiting

Conditions: Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting; HIV Infections

Summary: the primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by haart (highly active anti-retroviral therapy) in hiv and aids patients


Eligibility criteria:
inclusion criteria: * adherence to prior or current haart was or is being compromised, or haart was discontinued/interrupted due to nausea/vomiting; or beginning haart or switching from a regimen at the time of screening for this study that did not produce significant nausea and/or vomiting to a regimen with zidovudine or a protease inhibitor (with or without low dose ritonavir). exclusion criteria: * subjects with recent (within 30 days of randomization) or current opportunistic infection or neoplasm characteristic of aids (category c of the cdc classification system for hiv-1 infection, 1993 revised version).

Keywords: hiv aids nausea vomiting haart treatment experienced hiv infections
national prevalence and impact of noninvasive prenatal testing

Conditions: Aneuploidy

Summary: information on pregnant women undergoing non-invasive prenatal testing (nipt) at one of the obstetrix medical groups outpatient centers between january 2012 and june 2014 will be retrospectively gathered and an analysis of the impact and prevalence of nipt. this will be compared to a control group of pregnant women in those same practices undergoing prenatal testing during the months of january 2010-july 2010.

information regarding the frequency of non-invasive testing (nipt), the impact of screening on the need for and frequency of invasive testing, and the indications for testing are important for the clinicians in this country to not only understand the impact that this testing has had but also to plan for allocation of personnel and resources in their prenatal testing units, as well as many other more subtle changes including describing changes to referring clinicians and patients and projecting financial impacts. information on pregnant women undergoing nipt at one of the obstetrix medical groups outpatient centers between january 2012 and june 2014 will be retrospectively gathered and compared to a control group of pregnant women in those same practices undergoing invasive prenatal diagnostic testing for fetal karyotype (idtfk) during the months of january 2010-july 2010. an analysis of the impact of nipt will be done.

Eligibility criteria:
inclusion criteria: * pregnant women * presented to a participating obstetrix outpatient center for an invasive prenatal diagnostic testing for fetal karyotype (idtfk) (i.e. amniocentesis or cvs). * invasive prenatal diagnostic testing for fetal karyotype (idtfk) (i.e. amniocentesis or cvs) performed between january 2012 and june 2014 (a control group enrolled between january 2010 - july 2010) exclusion criteria: * patient less than 18 years of age * patients not receiving a invasive prenatal diagnostic testing for fetal karyotype (idtfk)(i.e. amniocentesis or cvs) at a participating study center * testing not done within the window for inclusion (jan 2012 - june 2014) or control group window (january 2010 - july 2010)

Keywords: aneuploidy trisomy 21 nipt
effectiveness of caudal epidural injections in treatment of chronic low back and lower extremity pain

Conditions: Low Back Pain

Summary: to demonstrate clinically significant improvements or lack thereof in the caudal epidural patients with our without steroids. to evaluate differences in outcomes in patients receiving steroids compared to those patients randomized to the local anesthetic group who did not receive steroids. to assess improvements among patients and compare steroid groups with each other and local anesthetic group. to evaluate and compare the adverse event profile in all patients

patients with chronic low back pain of at least 6 months duration, non-responsive to conservative management with nsaids, physical therapy or chiropractic treatment exercises. a single-center, prospective, controlled, double blinded, randomized study of patients in 4 groups. * group 1. local anesthetics only * group 2. local anesthetic with 6mg of non-particulate celestone * group 3. local anesthetic with 6 mg of brand name celestone * group 4. local anesthetic with 40 mg of alcohol-free depomedrol all patients will be unblinded in 12 months. non-responsive patients will be unblinded after 3 months and will be crossed over to a different group

Eligibility criteria:
inclusion criteria: * at least 18 years of age * history of chronic, function-limiting low back pain of at least 6 months duration * able to give voluntary, written informed consent to participate, * able to understand the investigation, cooperate with the procedures, and willing to return for follow-up * no recent surgical procedures within last three months exclusion criteria: * cauda equina symptoms and/or compressive radiculopathy * narcotic use of no greater than 100mg/day hydrocodone, 60mg methadone. or 100mg morphine * uncontrolled major depression or uncontrolled psychiatric disorder * uncontrolled or acute medical illnesses * chronic severe conditions that could interfere with outcome assessments * women who are pregnant or lactating * subjects who have participated in a clinical study with an investigational product within 30 days of enrollment * patients with multiple complaints involving concomitant hip osteoarthritis * inability to achieve proper positioning and inability to understand informed consent and protocol * history of adverse reaction to local anesthetic or anti-inflammatory drugs and history of gastrointestinal bleeding or ulcers

Keywords: caudal epidural injections lumbar disc herniation spinal stenosis discogenic pain post-lumbar laminectomy syndrome
investigating the specificity of neural correlates for emotion processing deficits in conduct disorder and autism spectrum disorders

Conditions: Autism-Spectrum Disorder; Conduct Disorder

Summary: this study is 1. to investigate the differential and shared neural underpinnings of facial emotion processing within conduct disorder (cd) and autism-spectrum disorder (asd) and 2. to investigate the interaction between deficits in emotion processing and dysfunctional cognitive control processes. differences in emotion processing and the underlying neural underpinnings of such differences will be assessed by means of functional magnetic resonance imaging (fmri) without any contrast agent, combined with adapted emotion processing paradigms and eye tracking techniques.


Eligibility criteria:
inclusion criteria: * for all participants: age between 10 and 18 years and an intelligence quotient score of 70 or higher. * for patient groups: confirmed clinical diagnoses according to diagnostic and statistical manual (dsm)-5 of cd or asd (depending on the group), without comorbid depression or anxiety psychological disorders. exclusion criteria: * for all participants: low intelligence (iq\<70, as they might otherwise not fully understand what they are expected to do inside the scanner), insufficient german language skills or any contraindications for mri (e.g. pregnancy, any non-removable metal within the subjects' body, claustrophobia). * for patient groups: severe developmental disorders, comorbid depressive and/or anxiety disorders will also be excluded from the study since it was shown that these patients might have problems in attention allocation under emotional stimulation. * for typically developing participants: suspicion of an undiagnosed clinical disorder

Keywords: callous-unemotional traits emotion processing deficits dysfunctional cognitive control processes
evaluating collagen cross-linking (ccl) treatment in norway

Conditions: Keratoconus

Summary: the purpose of this study is to assess safety, efficacy and stability of riboflavin-uv induced cross-linking of corneal collagen in reducing the progression of keratecatasia and in improving visual acuity. this is the first norwegian study concerning ccl.

the technique of corneal collagen cross-linking consists of photopolymerization of stromal fibers by combined action of a photosensitizing substance, riboflavin and ultraviolet type a rays (uva) from a solid-state uva source. photopolymerization increases the rigidity of corneal collagen and its resistance to keratectasia. it has been used to stop progression of keratectasia. corneal transplantation has been the only available option so far for treatment for keratectasia in its advanced stage in norway. the method of ccl using riboflavin and uv light is technically simple and much less invasive than corneal transplantation and it treats and prevents the underlying pathophysiological mechanism. it also does not reduce the chances for a successful corneal transplantation, in case that would still be necessary after ccl. the purpose of this study is to assess safety, efficacy and stability of riboflavin-uv induced cross-linking of corneal collagen in reducing the progression of keratecatasia and in improving visual acuity. this is the first norwegian study concerning ccl.

Eligibility criteria:
inclusion criteria: 1. age from 20 to 45 years 2. progressive keratectasia (primary or secondary) in an advanced stage 3. decreased best corrected visual acuity bellow 20/40, which cannot be further improved by use of soft contact lenses 4. rigid contact lenses are either not tolerated or do not improve visual acuity 5. no previous eye surgery (except for laser refractive surgery) 6. all patients must provide written informed consent to become a study subject 7. subjects able to return for scheduled follow-up examinations according to this protocol exclusion criteria: 1. corneal thickness \< 400 µm at thinnest position 2. keratometric - readings above 60 diopters 3. other active ocular disease than keratectasia 4. herpes keratitis 5. previous ocular surgery (other than laser refractive surgery) 6. patients who were immunocompromised, pregnant or who had atopic syndrome, connective tissue or autoimmune disease 7. patients with known sensitivity to study medication 8. subjects with intraocular pressure \> 23 mmhg by goldmann applanation tonometry, a history of glaucoma, or glaucoma suspects 9. subjects who intent to participate in other ophthalmic clinical trails during this clinical investigation

Keywords: keratoconus corneal cross-linking riboflavine ultraviolet type a rays (uva)
renal transplants in hepatitis c negative recipients with nucleic acid positive donors

Conditions: End Stage Renal Disease; Hepatitis C

Summary: in this study, individuals without hepatitis c infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis c infection and will be treated for hepatitis c at the same time. treatment will include glecaprevir 300 mg / pibrentasvir 120 mg (g-p) administered on-call to the operating room for the renal transplant procedure and continued for 4 weeks post-renal transplant.

in this study, individuals without hepatitis c infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis c infection and will be treated for hepatitis c at the same time. treatment will include glecaprevir 300 mg / pibrentasvir 120 mg (g-p) administered on-call to the operating room for the renal transplant procedure and continued for 4 weeks post-renal transplant. the participant will continue to be tested for hepatitis c for 12 weeks post-treatment. the primary hypothesis is that prophylactic treatment with glecaprevir/pibrentasvir before and after transplant will prevent the establishment of hcv infection in the recipients of kidneys from hcv-infected deceased donors. based on the success of preliminary studies, the objective of the study is to evaluate the safety and efficacy of 4 weeks of g-p as prophylaxis for hcv d+/r- kidney transplant.

Eligibility criteria:
recipient inclusion criteria * participants ≥ 40 years old * on the deceased donor kidney waitlist at johns hopkins hospital * awaiting a first or second kidney transplant * no available living kidney donors * on hemodialysis or peritoneal dialysis or stage 5 chronic kidney disease defined as a glomerular filtration rate \<15 ml/min for ≥ past 90 days * hcv-uninfected (by both antibody and rna pcr) and without any behavioral risk factors for contracting hcv other than being on hemodialysis * calculated panel reactive anti-human leukocyte antigen antibody (cpra) below 80% recipient exclusion criteria * plan to receive a multi-organ transplant * plan to receive a dual kidney transplant (including en bloc) * prior solid organ transplant * participating in another study that involves an intervention or investigational product * plan to receive a blood type incompatible kidney * history of human immunodeficiency (hiv), hepatitis c (hcv), or active hepatitis b (hbv) infection, defined as being on active antiviral treatment for hbv, detectable hepatitis b surface ag or detectable hepatitis b dna * unable to safely substitute or discontinue a medication that is contraindicated with the study medication * psychiatric or physical illness that in the opinion of the investigator would make it unsafe to proceed with transplantation or interfere with the ability of the subject to participate in the study
analgesic efficacy of intravenous lidocaine and/or ketamine

Conditions: Postoperative Pain

Summary: the aim of the present study is to evaluate the analgesic benefit of intravenous lidocaine and ketamine in the perioperative period of abdominal surgery.

optimal postoperative pain management facilitates rehabilitation immediately after abdominal surgery. multiple studies have demonstrated that successful postoperative analgesia also reduces perioperative complications and improves patient comfort, thereby providing many benefits for the patient. in acute postoperative pain management intravenous lidocaine and/or ketamine have been advocated because of their morphine-sparing effect.

Eligibility criteria:
inclusion criteria: * abdominal surgery by laparotomy exclusion criteria: * laparoscopy * history of chronic pain * opioid self-administration * psychiatric disorders * difficulties with communication * renal or hepatic dysfunction * asa physical status \> 3

Keywords: postoperative pain postoperative care intravenous lidocaine intravenous ketamine morphine consumption
corrected va with long-term follow-up after acrysof® intraocular lens (iol) implantation

Conditions: Pseudophakia

Summary: the purpose of this study is to compare the long-term visual acuity (va) with an acrylic iol to a silicone or polymethylmethacrylate (pmma) iol in cataract patients. this study will take place in japan.


Eligibility criteria:
inclusion criteria: * willing to provide voluntary consent and able to comprehend and sign the informed consent form; * pseudophakic patients implanted with an acrylic (acrysof®), pmma or silicone iol from 1994 to 2000; * clear intraocular media in study eye; * best-corrected visual acuity (decimal) within 3 months post-implantation of 0.8 (decimal va chart) or more in study eye; * no ocular or systemic condition which may affect visual acuity in study eye; * other protocol-specified inclusion criteria may apply. exclusion criteria: * complications that may impact visual acuity in study eye at the time of the prospective visit, such as glaucoma, diabetic retinitis, ocular inflammatory disease, retinal detachment, and others as specified in the protocol; * previous refractive surgery in study eye; * previous iol exchange in study eye; * other protocol-specified exclusion criteria may apply.
motivational therapy for substance users with depression

Conditions: Depression; Substance Dependence

Summary: the primary objective of the study is to test the incremental efficacy and outcomes of an aftercare program of cognitive behavioral therapy combined with motivational therapy (cbt-mt) relative to treatment as usual (tau) in improving depression, substance use, and healthcare outcomes in a population with drug dependence and comorbid major depressive disorder (mdd). the investigators expect that among drug-dependent patients with comorbid mdd, cbt-mt will yield better clinical outcomes relative to tau in reducing depressive symptoms and substance use and improving healthcare outcomes during treatment. secondary objectives: 1. test efficacy and outcomes of cbt-mt and tau 2. evaluate the differential effect of cbt-mt versus tau on hiv-risk behavior of participants, 3. to evaluate the impact of cognitive functioning on treatment retention and outcomes, and 4. to explore additional psychosocial, demographic, and diagnostic factors (e.g., age, gender, education level, motivation for change, social support) that may be associated with treatment outcome and retention in this high need population.

this study will include approximately 80 participants randomized to either 12 weeks of motivational therapy or treatment as usual. both treatments will meet once weekly for 60 minutes. participants will be recruited from the adult partial hospitalization program at university of california, los angeles. during the active treatment phase, participants will attend clinic weekly for collection of data and urine specimens. 1. for those randomly assigned to cbt-mt, they will meet with a therapist in a group format for 60-minute sessions once weekly. a. each cbt-mt session will begin with 20 minutes of motivational therapy (mt), followed by 40 minutes of cbt content. 2. those randomly assigned to tau, they will attend a weekly 60-minute dual recovery anonymous self-help group.

Eligibility criteria:
inclusion criteria: 1. age 18 or over 2. dsm-iv diagnosis of substance dependence (cannabis, stimulant, opioid, or prescription drug) or dsm-iv diagnosis of alcohol dependence and abuse of cannabis, stimulant, opioid, or prescription drug 3. diagnostic and statistical manual -iv diagnosis of lifetime major depressive disorder (mdd) 4. bdi-ii score of 13 or greater exclusion criteria: 1. presence of life threatening or unstable medical illness 2. lack of proficiency in english 3. current homelessness (unless residing in a recovery home for which contact information can be provided) 4. psychiatric symptoms warranting safety concerns or inpatient treatment, including acute suicide risk 5. present diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder.

Keywords: co-occurring disorders depression substance dependence motivational therapy aftercare cognitive behavioral therapy
bimetric-10: investigation of patients who have underwent total hip arthroplasty with a cemented bi-metric stem

Conditions: Osteoarthrosis

Summary: this is a 10 year follow-up investigation of patients who have underwent total hip arthroplasty with a cemented bimetric stem.


Eligibility criteria:
inclusion criteria: * osteoarthrosis exclusion criteria: * malignancies

Keywords: osteoarthritis